Stockscreener 앱 받기
143.19
0.87%
1.23
시간 외 거래:
143.19
전일 마감가:
$141.96
열려 있는:
$142.35
하루 거래량:
744.40K
Relative Volume:
0.86
시가총액:
$14.20B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
48.54
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-2.84%
1개월 성능:
+4.50%
6개월 성능:
+30.55%
1년 성능:
+18.80%
1일 변동 폭
$140.82
$143.87
1주일 범위
$133.61
$144.98
52주 변동 폭
$84.23
$154.61
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.19 | 14.15B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
124.46 | 63.97B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.56 | 42.40B | 29.63B | 260.53M | 4.77B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.32 | 41.77B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.46 | 23.54B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
437.33 | 18.89B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
What Makes Neurocrine (NBIX) a New Strong Buy Stock - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $179.00 - MarketBeat
Why Neurocrine Biosciences Inc. stock remains resilientJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Is Neurocrine Biosciences Inc. stock trading near support levelsBreakout Watch & Free Risk Controlled Daily Trade Plans - newser.com
Can Neurocrine Biosciences Inc. stock weather global recessionSwing Trade & Fast Momentum Stock Entry Tips - newser.com
How Neurocrine Biosciences Inc. stock responds to policy changes2025 Price Momentum & Free Expert Approved Momentum Trade Ideas - newser.com
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Tredje AP fonden - MarketBeat
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherEarnings Performance Report & Weekly Stock Performance Updates - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock attractive for dividend growthWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Profit Report & AI Driven Price Forecasts - newser.com
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Recap & Expert Approved Momentum Ideas - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyCPI Data & Stepwise Swing Trade Plans - newser.com
Neurocrine Biosciences, Inc. (NBIX) Stock Forecasts - Yahoo! Finance Canada
Measuring Neurocrine Biosciences Inc.’s beta against major indices2025 Trading Volume Trends & Daily Profit Maximizing Tips - newser.com
Published on: 2025-11-03 22:02:17 - newser.com
Neurocrine Biosciences, Inc. (NBIX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikes2025 Dividend Review & Verified Entry Point Signals - newser.com
Neurocrine taps China biotech for NLRP3 programs: Deals Report - BioCentury
Key facts: JP Morgan Raises Neurocrine Target to $179; TransThera Deal Worth $881.5M - TradingView
Neurocrine Bio. stock price target raised to $147 by BMO Capital - Investing.com Canada
What data driven models say about Neurocrine Biosciences Inc.’s futureWeekly Stock Report & Daily Oversold Bounce Ideas - newser.com
Applying sector rotation models to Neurocrine Biosciences Inc.Market Volume Report & Risk Adjusted Swing Trade Ideas - newser.com
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stockJuly 2025 WrapUp & Free Daily Entry Point Trade Alerts - newser.com
Neurocrine Biosciences (NBIX): Assessing Valuation After Strong Q3 Results and Pipeline Progress - simplywall.st
Can Neurocrine Biosciences Inc. stock sustain revenue growth2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
What moving averages say about Neurocrine Biosciences Inc.Portfolio Performance Report & Accurate Buy Signal Alerts - newser.com
TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience - MarketScreener
Transthera Sciences (Nanjing) Inc announces collaboration with Neurocrine Biosciences Inc for NLRP3 inhibitors - MarketScreener
Transthera Sciences (Nanjing) Inc Announces Collaboration With Neurocrine Biosciences Inc For NLRP3 Inhibitors - TradingView
TransThera Sciences Partners with Neurocrine for NLRP3 Inhibitors Development - TipRanks
How risky is Neurocrine Biosciences Inc. stock nowEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
1,945 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Daymark Wealth Partners LLC - MarketBeat
What analysts say about Neurocrine Biosciences Inc stockMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Neurocrine Biosciences, Inc. (NBIX) Stock forecasts - Yahoo! Finance UK
Is It Time to Lock in Profits on Winsol Engineers Limited StockPrice Volatility Patterns & Exceptional Trading Strategies - earlytimes.in
Cantor Fitzgerald Brokers Raise Earnings Estimates for NBIX - MarketBeat
Brighton Jones LLC Invests $351,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Short interest data insights for Neurocrine Biosciences Inc.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.38%
0.45%
자본화:
|
볼륨(24시간):